ARSArs Technica·4dHealth
score-0.60
Cost and access barriers drive millions of US users to unapproved GLP-1s and modified usage
Original
Millions in US use unapproved GLP-1s—and use them in unapproved ways
“Highlights public health risks from unapproved drugs driven by cost barriers, implying systemic failure in access.”